These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10482462)

  • 21. Ligand association with the rabbit kidney and brain Y1, Y2 and Y5-like neuropeptide Y (NPY) receptors shows large subtype-related differences in sensitivity to chaotropic and alkylating agents.
    Parker SL; Parker MS
    Regul Pept; 2000 Feb; 87(1-3):59-72. PubMed ID: 10710289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel analogues of neuropeptide Y with a preference for the Y1-receptor.
    Söll RM; Dinger MC; Lundell I; Larhammer D; Beck-Sickinger AG
    Eur J Biochem; 2001 May; 268(10):2828-37. PubMed ID: 11358498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic polypeptide-preferring (NPY Y4) receptor.
    Schober DA; Van Abbema AM; Smiley DL; Bruns RF; Gehlert DR
    Peptides; 1998; 19(3):537-42. PubMed ID: 9533642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonpeptide peptidomimetic antagonists of the neuropeptide Y receptor: benextramine analogs with selectivity for the peripheral Y2 receptor.
    Chaurasia C; Misse G; Tessel R; Doughty MB
    J Med Chem; 1994 Jul; 37(14):2242-8. PubMed ID: 7913507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
    Kakui N; Tanaka J; Tabata Y; Asai K; Masuda N; Miyara T; Nakatani Y; Ohsawa F; Nishikawa N; Sugai M; Suzuki M; Aoki K; Kitaguchi H
    J Pharmacol Exp Ther; 2006 May; 317(2):562-70. PubMed ID: 16436501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
    Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
    J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures.
    Aiglstorfer I; Uffrecht A; Gessele K; Moser C; Schuster A; Merz S; Malawska B; Bernhardt G; Dove S; Buschauer A
    Regul Pept; 1998 Sep; 75-76():9-21. PubMed ID: 9802389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists.
    Parker EM; Babij CK; Balasubramaniam A; Burrier RE; Guzzi M; Hamud F; Mukhopadhyay G; Rudinski MS; Tao Z; Tice M; Xia L; Mullins DE; Salisbury BG
    Eur J Pharmacol; 1998 May; 349(1):97-105. PubMed ID: 9669502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs.
    MacNeil DJ
    Curr Top Med Chem; 2007; 7(17):1721-33. PubMed ID: 17979781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
    Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
    Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists.
    Norman MH; Chen N; Chen Z; Fotsch C; Hale C; Han N; Hurt R; Jenkins T; Kincaid J; Liu L; Lu Y; Moreno O; Santora VJ; Sonnenberg JD; Karbon W
    J Med Chem; 2000 Nov; 43(22):4288-312. PubMed ID: 11063624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist.
    Doods H; Gaida W; Wieland HA; Dollinger H; Schnorrenberg G; Esser F; Engel W; Eberlein W; Rudolf K
    Eur J Pharmacol; 1999 Nov; 384(2-3):R3-5. PubMed ID: 10611450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.
    Berglund MM; Saar K; Lundell I; Langel U; Larhammar D
    Neuropeptides; 2001; 35(3-4):148-53. PubMed ID: 11884204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.
    Brothers SP; Saldanha SA; Spicer TP; Cameron M; Mercer BA; Chase P; McDonald P; Wahlestedt C; Hodder PS
    Mol Pharmacol; 2010 Jan; 77(1):46-57. PubMed ID: 19837904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
    Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
    J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
    Doods HN; Wienen W; Entzeroth M; Rudolf K; Eberlein W; Engel W; Wieland HA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):136-42. PubMed ID: 7562541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological characterization of cloned chicken neuropeptide Y receptors Y1 and Y5.
    Holmberg SK; Mikko S; Boswell T; Zoorob R; Larhammar D
    J Neurochem; 2002 May; 81(3):462-71. PubMed ID: 12065655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropeptide Y modulates functions of inflammatory cells in the rat: distinct role for Y1, Y2 and Y5 receptors.
    Mitić K; Stanojević S; Kuštrimović N; Vujić V; Dimitrijević M
    Peptides; 2011 Aug; 32(8):1626-33. PubMed ID: 21699939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward Labeled Argininamide-Type NPY Y1 Receptor Antagonists: Identification of a Favorable Propionylation Site in BIBO3304.
    Keller M; Schindler L; Bernhardt G; Buschauer A
    Arch Pharm (Weinheim); 2015 Jun; 348(6):390-8. PubMed ID: 25884646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations.
    Beck-Sickinger AG; Wieland HA; Wittneben H; Willim KD; Rudolf K; Jung G
    Eur J Biochem; 1994 Nov; 225(3):947-58. PubMed ID: 7957231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.